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Introduction. The mechanisms underlying the association between insulin resistance and intrahepatic lipid (IHL) accumulation
are not completely understood. We sought to determine whether this association was explained by differences in fasting non-
esterified fatty acid (NEFA) levels and/or NEFA suppression after oral glucose loading. Materials and Methods. We performed a
cross-sectional analysis of 70 healthy participants in the Hertfordshire Physical Activity Trial (39 males, age 71.3 ± 2.4 years) who
underwent oral glucose tolerance testing with glucose, insulin, and NEFA levels measured over two hours. IHL was quantified
with magnetic resonance spectroscopy. Insulin sensitivity was measured with the oral glucose insulin sensitivity (OGIS) model,
the leptin: adiponectin ratio (LAR), and the homeostasis model assessment (HOMA). Results. Measures of insulin sensitivity were
not associated with fasting NEFA levels, but OGIS was strongly associated with NEFA suppression at 30 minutes and strongly
inversely associated with IHL. Moreover, LAR was strongly inversely associated with NEFA suppression and strongly associated
with IHL. This latter association (beta = 1.11 [1.01, 1.21], 𝑃 = 0.026) was explained by reduced NEFA suppression (𝑃 = 0.24 after
adjustment). Conclusions. Impaired postprandial NEFA suppression, but not fasting NEFA, contributes to the strong and well-
established association between whole body insulin resistance and liver fat accumulation.
1. Introduction
Excess intrahepatic lipid (IHL) accumulation (nonalcoholic
fatty liver disease, NAFLD) is an important component of
the spectrum of metabolic derangements associated with
central obesity and insulin resistance [1]. Studies elucidating
the mechanistic basis for these associations have suggested
that increased circulating nonesterified fatty acids (NEFAs)
lead to elevations in IHL [2] and that these NEFAs are
generated predominantly from lipolysis in white adipose
tissue [3]. Inhibition of glucose oxidation by fatty acids is
known to be an important feature of the glucose-fatty acid (or
Randle) cycle [4], such that increases in plasma NEFA levels
during starvation or in the diabetic state result in greater
fat oxidation at the expense of glucose oxidation. Although
insulin-mediated suppression of circulating NEFA levels is a
2 International Journal of Endocrinology
robust marker of adipocyte insulin sensitivity [5, 6], elevated
fasting NEFA levels are generally considered to be the cause
of hepatic fat accumulation in obese insulin-resistant states
[7]. Furthermore, a recent study of 42 nonobese adults which
measured postabsorptive fatty acid disposal with labeled
palmitate found no association between this and whole body
or peripheral insulin sensitivity [8]. A formal comparison
of the strengths of the associations between fasting and
suppressed NEFA levels is therefore warranted. Our first
objective was to compare the strengths of the associations, if
any, between whole body insulin sensitivity (as the exposure)
and fasting NEFA levels versus NEFA suppression after oral
glucose loading (at 30 and 60 minutes, as the “outcomes”).
For this, we conducted a post hoc, cross-sectional analysis of
metabolic and anthropometric data from a cohort of healthy
older adults who participated in the Hertfordshire Physical
Activity Trial (HPAT) [9].
NEFA suppression is impaired in type 2 diabetes [10] and
NAFLD [11], but whether the well-established associations
between insulin resistance, impaired NEFA suppression, and
IHL persist in apparently healthy older individuals with-
out prevalent NAFLD or diabetes is not known. Also, the
extent to which impaired NEFA suppression modulates the
accumulation of IHL has not previously been determined.
Chronic inflammation within adipose tissue has been impli-
cated in the pathogenesis of peripheral insulin resistance
[12], and levels of fat-derived hormones (specifically the
leptin : adiponectin ratio, LAR) have recently been shown to
correlatewell with clampmeasures ofwhole body insulin sen-
sitivity [13]. Therefore, our second objective was to estimate
the associations between model-based measures of insulin
resistance and impaired NEFA suppression as exposures and
IHL as the outcome and to determine the extent to which
the associations between insulin resistance and IHL were
explained by variations in NEFA suppression.
2. Methods
Therationale and design for theHertfordshire Physical Activ-
ity Trial (ISRCTN 60986572) have been described previously
[9]. Data reported here relate to post hoc, cross-sectional
analyses of volunteers’ anthropometric and metabolic char-
acteristics at the time of their entry into the study. Each
participant provided written informed consent. The original
study protocol was approved by the Hertfordshire Research
Ethics Committee (LREC ref. 05/Q0201/23).
Trial participants were recruited from the Hertfordshire
Cohort Study, consisting of men and women born in Hert-
fordshire, UK, between 1931 and 39 and still residing there
[14]. Specifically, those who were deemed to be potentially
suitable by their general practitioner for inclusion in a
supervised aerobic exercise programme andwho lived within
ten miles of the exercise facility were invited to participate,
as described previously [9]. Those with known diabetes,
untreated or unstable ischaemic heart disease, or anymedical
condition that would preclude participation in an exercise
programme were excluded from the trial. However, partici-
pants with incident diabetes (diagnosed at the time of entry to
this study) were included in these analyses. Recruits attended
the clinical research facility after an overnight fast. Of 106who
attended the screening visit, six were deemed to be unsuitable
for the study because of poor mobility, preexisting diabetes,
symptoms or signs suggestive of untreated ischaemic heart
disease, or a combination of these factors were excluded.
Of the remaining 100, MR imaging and spectroscopy were
not performed on 30 individuals who had claustrophobia,
cardiac pacemakers, or metal implants. Thus, 70 participants
who enrolled in the study had baseline liver spectroscopy
measures performed and constitute the cohort described
herein.
All measurements were undertaken by trained staff
adhering to standard operating procedures. Weight was
measured on a Tanita (Tokyo, Japan) scale and height with a
Seca (Hamburg, Germany) wall-mounted stadiometer. Waist
circumference was measured using a D-loop nonstretch
fibreglass tape measure and defined as the midpoint between
the lower costal margin and the level of the superior iliac
crests. Blood pressure was measured with an oscillometric
device (Omron, Kyoto, Japan) using the right arm, after
participants were seated quietly for five minutes. A dual
energy X-ray absorptiometry (DEXA) scan (Lunar Prodigy
Advance, GE Healthcare, Bedford, UK) was used to measure
lean mass and body fat percentage [15]. Magnetic resonance
measures of intrahepatic lipid (IHL) and visceral adipose
tissue (VAT) were conducted on a whole body Siemens
3T Tim Trio scanner (Erlangen, Germany), as described
previously [9]. A questionnaire was used to quantify alcohol
consumption in units per week.
A standard 75 g oral glucose tolerance test (OGTT) was
performed. Fasting samples were taken for glucose, insulin,
C-peptide, lipid profile, NEFA, leptin, and adiponectin.
Glucose was measured using a hexokinase assay (Siemens,
Frimley, UK). Insulin and C-peptide were measured using
a fluorometric autoDELFIA immunoassay (PerkinElmer Life
Sciences, Turku, Finland). NEFA levels were measured on
a colorimetric assay (Roche Diagnostics, Burgess Hill, UK).
Leptin and adiponectin were both measured using a DELFIA
assay (R&D Systems Europe, Abingdon, UK). After ingestion
of glucose, further samples were taken every 30 minutes
over two hours. Samples for glucose and lipid profiles were
processed immediately, while those for insulin, C-peptide,
NEFA, leptin, and adiponectin were spun and frozen for
subsequent batch analysis. All samples were processed in
the same laboratory. The oral glucose insulin sensitivity
(OGIS) model [16] was used to determine peripheral insulin
sensitivity based on dynamic insulin and glucose responses
during the OGTT, primarilymediated through insulin effects
on muscle. Additionally, we used the leptin : adiponectin
ratio [13] as an index of whole body insulin sensitivity and
the homeostasis model assessment (HOMA) as an index
of hepatic insulin sensitivity [17]. The degree of insulin-
mediated NEFA suppression was determined by calculating
the percentage reduction in NEFA levels 30 and 60 minutes
after glucose loading.The area under the concentration curve
(AUC) for NEFA during the OGTT was calculated with the
trapezium rule.
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The anthropometric and metabolic characteristics of
the study participants were summarised using means and
standard deviations. To estimate the association between
each of these characteristics and IHL, linear regression was
used with log(IHL) as the outcome, and each characteristic
standardised to have mean 0 and variance 1. The models also
included age, gender, alcohol consumption (units per week,
self-reported), and, where relevant, MRI-derived visceral fat
area. For each exposure, the beta coefficient and 95% confi-
dence limits were exponentiated, giving a ratio of geometric
mean IHL per standard deviation increase in the exposure.
The associations between standardised measures of insulin
sensitivity (OGIS, LAR, andHOMA) and IHLwere estimated
using the same method, with adjustment for age, gender,
MRI-derived visceral fat area, and alcohol consumption. The
potential confounding effect of NEFA suppression at 30 and
60 minutes was also explored.
3. Results
Of the 70 HPAT participants included in these analyses,
39 were men. Mean ± SD age was 71.3 ± 2.4 years.
Systolic and diastolic blood pressures were 137 ± 18 and
75 ± 9mmHg, respectively. The median IHL content was
3.6% (range 0.2–34.5%), while 42% of participants had IHL
>5.5%, thus exceeding the arbitrary diagnostic threshold
for NAFLD [18]. Three participants were found to have
incident, asymptomatic type 2 diabetes based on OGTT
results and were included in all analyses. Data relating to
other anthropometric and metabolic characteristics of the
cohort are summarised in Table 1. The associations between
these characteristics and IHL are also shown in Table 1.
These associations have been standardised in order to allow
a comparison of their relative strengths. So, for example,
each standard deviation rise in LAR was associated with a
49% increase in IHL, while each standard deviation rise in
adiponectin was associated with a 48% reduction in IHL.
Different measures of adiposity were positively associated
with increased IHL, as expected. There were significant
associations between each measure of insulin sensitivity
and IHL, in the anticipated directions. NEFA suppression
after oral glucose loading was inversely associated with IHL
as shown in Table 1 and Figure 1. Results were similar for
unadjusted analyses (data not shown).
To assess the relative strengths of the associations between
insulin sensitivity and fasting as opposed to suppressed
NEFA levels, we standardised OGIS, LAR, and HOMA.
There were no significant associations between any indices
of insulin sensitivity and fasting NEFA levels (Table 2), nor
did HOMA correlate with measures of NEFA suppression.
The associations between both OGIS and LAR and NEFA
suppression were stronger for the 30-minute than the 60-
minute values (Table 2) and were not significant for any of
the 120-minute values (data not shown). OGIS and LAR had
equivalent (though opposing) strengths of association with
NEFA suppression at 30 minutes although the significance
of the inverse associations at 60 minutes for LAR was
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Figure 1: NEFA levels during standard 120-minute 75 g oral glucose
tolerance test in participants with intrahepatic lipid ≤5.5% (dashed
line) versus those with intrahepatic lipid >5.5%, that is, NAFLD
(solid line). Data are presented as mean ± SE. 𝑃trend values are
derived from linear regression modelling with IHL treated as a
continuous outcome variable and the exposure being the area under
the NEFA curve, adjusted for age, gender, alcohol consumption, and
visceral fat area.
strengthened after adjusting for age, gender, MR VAT, and
alcohol consumption.
In order to determine the extent to which impairedNEFA
suppression contributes to the observed inverse associations
between insulin sensitivity (as exposure) and liver fat (as
outcome), we compared these associations before and after
adjusting for NEFA suppression (Table 3). After adjusting for
NEFA suppression at 30 minutes, the positive association
between LAR and IHL was attenuated and lost statistical
significance. However, when OGIS or HOMA was treated
as the insulin sensitivity measure, there was no attenua-
tion of the association with IHL after adjusting for NEFA
suppression. These results were similar after adjusting for
NEFA suppression at 60 minutes, as shown. In order to avoid
any confounding effects of medications known to influence
lipidmetabolism, we conducted subgroup analyses excluding
those taking statin medications (𝑛 = 14, 20%) and those
taking beta-blockers (𝑛 = 12, 17%), but these did not change
our findings (data not shown).
4. Discussion
We found strong and consistent associations between OGIS
and LAR (but not HOMA) and NEFA suppression. The
absence of any associations with fasting NEFA levels is con-
sistent with other recent observations [19] and suggests that
fasting NEFA levels may be influenced by other factors such
as catecholamine or growth hormone levels, whereas post-
prandial NEFA suppression is predominantly determined by
insulin. NEFA levels are very promptly suppressed by insulin,
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Table 1: Anthropometric and metabolic characteristics of study participants and their associations (after standardization) with intrahepatic
lipid as the outcome measure.
Variable Mean ± SD Range Standardised betaa 95% C.I. P
Weight (Kg)b 76.0 ± 13.8 48.6–111.7 2.51 [1.86, 3.38] <0.001
BMI (kg m−2)b 26.6 ± 3.5 20.7–37.8 2.03 [1.56, 2.64] <0.001
Waist (cm)b 96.7 ± 11.9 72.3–120.5 2.70 [2.05, 3.55] <0.001
Total fat (%)b 32.8 ± 7.5 15.9–48.2 2.26 [1.59, 3.22] <0.001
MRI VAT (cm2)b 127.7 ± 65.9 29.2–285.3 2.64 [2.02, 3.44] <0.001
Alcohol (units/week) 6.5 ± 9.7 0–42 0.86 [0.67, 1.11] 0.24
ALT (iu/L) 28.0 ± 19.9 11–175 1.28 [1.03, 1.60] 0.029
Fasting NEFA (mmol/L) 684.6 ± 208.9 286–1332 1.01 [0.77, 1.33] 0.94
AUCNEFA (mmol/Lmin) 35435 ± 10353 19680–66180 1.35 [1.06, 1.74] 0.018
NEFA Suppression at 30minutes (%) 38.6 ± 19.5 −11.2–81.9 0.75 [0.59, 0.96] 0.020
NEFA Suppression at 60minutes (%) 67.8 ± 15.2 25.2–89.2 0.75 [0.58, 0.96] 0.023
Leptin (ng/mL) 15.3 ± 13.8 0.1–65.3 1.45 [1.002, 2.09] 0.049
Adiponectin (ug/mL) 7.7 ± 4.9 2.2–24.1 0.52 [0.40, 0.69] <0.001
LAR (ng/ug) 3.0 ± 3.6 0.01–16.3 1.49 [1.05, 2.10] 0.026
Fasting glucose (mmol/L) 5.0 ± 0.5 4.1–6.4 1.49 [1.19, 1.85] 0.001
2-hour glucose (mmol/L) 7.3 ± 2.0 3.9–12.3 1.44 [1.15, 1.80] 0.002
HbA1c (%) 5.7 ± 0.3 4.9–6.4 1.11 [0.88, 1.39] 0.39
Fasting insulin (pmol/L) 64.7 ± 40.3 18.1–288 1.46 [1.13, 1.90] 0.005
HOMA-IR (%) 1.2 ± 0.7 0.4–5.0 1.50 [1.16, 1.92] 0.002
OGIS (mLmin−1 m−2) 409.3 ± 62.7 223–548 0.56 [0.43, 0.72] <0.001
Intrahepatic lipid was log transformed in all analyses, and then beta coefficients and confidence intervals were back transformed.
aBeta represents the ratio of geometric mean IHL per 1 standard deviation increase in relevant exposure. Therefore, standardized beta values > 1 represent a
positive association, and values < 1 represent a negative association. All analyses are adjusted for age, gender, alcohol consumption, and MRI-derived visceral
fat area (MRI VAT).
bThese analyses are not adjusted for MRI VAT.
HOMA: homeostasis model assessment.
LAR: leptin : adiponectin ratio.
NEFA: nonesterified fatty acids.
OGIS: oral glucose insulin sensitivity.
Table 2: Associations between standardised measures of insulin sensitivity (as exposures) andmeasures of NEFAmetabolism (as outcomes).
Fasting NEFA NEFA suppression at 30minutes NEFA suppression at 60minutes
𝛽 95% CI P 𝛽 95% CI P 𝛽 95% CI P
Unadjusted
zLAR −17.8 [−75.8, 40.3] 0.54 −7.9 [−13.0, −2.8] 0.003 −6.0 [−10.0, −2.1] 0.003
zOGIS 10.4 [-46.4, 67.2] 0.72 9.1 [4.2, 13.9] <0.001 5.6 [1.6, 9.5] 0.006
zHOMA 15.6 [36.2, 67.4] 0.55 −3.6 [−8.4, 1.2] 0.14 −1.8 −5.6, 2.1 0.35
Adjusteda
zLAR −31.6 [−105.3, 42.1] 0.39 −11.9 [−18.7, −5.1] 0.001 −7.3 [−12.6, -2.0] 0.008
zOGIS −25.0 [−88.3, 38.3] 0.43 11.0 [5.4, 16.7] <0.001 4.4 [−0.2, 9.1] 0.062
zHOMA 49.4 [−4.5, 103.3] 0.07 −3.6 [−9.1, 1.9] 0.19 0.02 [−4.2, 4.2] 0.99
aAdjusted for age, gender, MR VAT, and alcohol consumption.
NEFA: nonesterified fatty acids.
zHOMA: standardised homeostasis model assessment.
zLAR: standardised leptin : adiponectin ratio.
zOGIS: standardised oral glucose insulin sensitivity.
so the observation that NEFA suppression at 30 rather than
60 or 120 minutes is a stronger marker of insulin sensitivity is
not unexpected.
The similar strengths of associations for LAR and OGIS
with NEFA suppression are potentially interesting. (They
occurred in opposite directions because the former measures
insulin resistance while the latter measures insulin sensitiv-
ity.) Given that NEFA suppression is mediated by adipose
tissue insulin sensitivity [6], we anticipated that LARmight be
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Table 3: Associations between measures of insulin sensitivity and intrahepatic lipid before and after adjusting for NEFA suppression at 30
and 60minutes.
Model 1a Model 2b Model 3c
𝛽 95% CI P 𝛽 95% CI P 𝛽 95% CI P
LAR 1.11 [1.01, 1.21] 0.026 1.05 [0.96, 1.16] 0.29 1.06 [0.96, 1.16] 0.24
OGIS 0.99 [0.99, 1.00] <0.001 0.99 [0.99, 1.00] <0.001 0.99 [0.99, 0.99] <0.001
HOMA-IR 1.78 [1.24, 2.55] 0.002 1.69 [1.20, 2.38] 0.003 1.79 [1.28, 2.49] 0.001
Intrahepatic lipid was log transformed in all analyses, and then beta coefficients and confidence intervals were back transformed.
aBeta represents the ratio of geometric mean IHL per 1 unit increase in relevant exposure. Association with intrahepatic lipid is adjusted for age, gender, MR
VAT, and alcohol consumption.
bAs per model 1 with additional adjustment for NEFA suppression at 30minutes.
cAs per model 1 with additional adjustment for NEFA suppression at 60minutes.
HOMA: homeostasis model assessment.
LAR: leptin : adiponectin ratio.
OGIS: oral glucose insulin sensitivity.
more strongly associated with it than OGIS, the latter reflect-
ing insulin-mediated glucose disposal primarily in skeletal
muscle, but this was not the case. However, LAR has only
previously been shown to correlate with whole body insulin
sensitivity rather than fat tissue sensitivity specifically [13],
andwhile leptin and adiponectin are derived exclusively from
adipocytes rather than merely acting as markers of adipocyte
inflammation, they may actively modulate insulin action in
other tissues.The absence of an association between impaired
NEFA suppression and HOMA (which is generally regarded
as an index of hepatic insulin resistance) suggests that even
though the liver is capable of disposal of free fatty acids
[20], variations in hepatic insulin sensitivity have a relatively
small impact on wholebody fatty acid disposal. Lastly, the
finding that the inverse association between NEFAAUC and
IHL was twice as strong as that for NEFA suppression at
30 or 60 minutes probably reflects the bidimensional nature
of the AUC measure (see Figure 1), where fasting as well as
postprandial NEFA levels have a multiplicative effect on this
variable.
Our data indicate that excess body fat (particularly
visceral fat), insulin resistance, and impaired suppression
of NEFA levels after oral glucose loading are all directly
associated with increased IHL in older individuals. In order
to explore the mechanistic basis for the association between
peripheral insulin resistance and NAFLD, we adjusted for
NEFA suppression and found that this association was sig-
nificantly attenuated for LAR but not for OGIS or HOMA.
For these analyses, we also adjusted for central adiposity
and chose the MRI-derived cross-sectional visceral fat area
over other measures of fatness (BMI, body fat %, and waist
circumference) because it was most strongly associated with
liver fat content (Table 1). However, results were similar
when these other measures of fatness were used (data not
shown). So reduced suppression of fatty acids explains the
association between LAR, but not OGIS or HOMA, and liver
fat content. This suggests that while OGIS and LAR are both
indices of whole body insulin sensitivity, adipocyte insulin
resistance is reflected to a greater extent with LAR than with
OGIS or HOMA. These results also suggest that there are
other mechanisms apart from impaired NEFA suppression
linking insulin resistance and NAFLD, such as dysregulated
de novo lipogenesis and hepatocyte endoplasmic reticulum
stress [21].
This study has a number of important strengths. Very
detailed anthropometric and metabolic characterisation was
conducted in each participant, and results were consistent
across differentmeasures of body fatness and insulin sensitiv-
ity. MR spectroscopy is the most robust noninvasive method
for quantifying IHL. Rather than comparing categories of
steatosis, body fatness, or glycaemic status, as many studies
do, all our measures are continuous and represent the
distributions in a relatively healthy cohort of older white
participants. The study also has some limitations. It is a
post-hoc analysis of data from a subgroup of individuals
who were willing to participate in an exercise trial. All
participants in the trial were White. Thus, our results may
not be generalisable to all older people or those who would
be less amenable to an exercise intervention, for whatever
reason. Also, only 70% of people who enrolled in the trial
had MR imaging at baseline, while others were unwilling or
were too large for the scanner, which may have introduced
bias.
Nonetheless, the 42% prevalence of NAFLD was higher
than we anticipated, and there was a substantial level of
metabolic disturbance in this cohort, particularly in rela-
tion to the number of individuals with abnormal glucose
metabolism during the OGTT. It is important to note that
these abnormalities were only detected through participation
in the study and were not diagnosed prior to it (and so were
not “prevalent” as such). All of these individuals volunteered
to participate in a 12-week exercise intervention. Diabetes
was one of several exclusion criteria. Nonetheless, three
of the 70 individuals (4.3%) had newly diagnosed type 2
diabetes at entry to the study, while a further 27 (38.6%) had
abnormal glucose metabolism. None of these had symptoms
of hyperglycaemia, nor were they on treatment for it at the
time of testing. Therefore, we felt it is appropriate to include
them in the analysis. These participants were “apparently
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healthy,” and within a cohort of this age, a certain level
of undiagnosed metabolic disease, be it diabetes or liver
steatosis, is to be expected, so to be able to quantify this so
precisely in the paper contributes to the novelty of our find-
ings. So our observation too that impairedNEFA suppression
does mediate the association between whole body insulin
resistance, measured with LAR and liver steatosis.
5. Conclusions
In our experience, there is a widely held perception amongst
scientists and clinicians in the field ofmetabolism that fasting
NEFA levels are strongly positively associated with insulin
resistance. However, in conducting a formal comparison of
the relative strengths of the associations between fasting
versus suppressed NEFA levels, we have confirmed that the
degree of NEFA suppression is far more strongly associated
with indices of insulin resistance, namely, OGIS and LAR,
and is thus important from a clinical and pathophysiological
point of view. We have been careful to take account of
confounding factors such as age [22], sex [8], and other
factors likely to influence these associations such as alcohol
consumption.We believe that the relatively good health of the
participants in this studymakes the findings described above,
particularly in relation to the high prevalence of NAFLD,
even more novel and compelling.
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